Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer

NCT02393794 is registered in ClinicalTrials.gov with Priyanka Sharma as lead sponsor.

NCT NCT02393794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer
Lead sponsor
Priyanka Sharma
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 17, 2015
Completion date
July 31, 2026
Enrollment
51 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple-negative breast cancer